Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group

Roberto Luksch, Giovanni Grignani, Paolo D'Angelo, Arcangelo Prete, Nadia Puma, Marta Podda, Michela Casanova, Andrea Ferrari, Carlo Morosi, Franca Fagioli, Massimo Aglietta, Stefano Ferrari, Piero Picci, Maura Massimino

Research output: Contribution to journalArticlepeer-review

Abstract

The aim was to assess the activity of cisplatin (CDDP) in Ewing sarcoma (ES). The study consisted of front-line window therapy with CDDP 120 mg/sqm every 3 weeks for two courses in children and young adults with primary disseminated ES. Response was assessed using the Response Evaluation Criteria in Solid Tumours criteria, and Simon's two-stage design was applied. Twelve consecutive patients were enrolled in stage 1. Only one objective response was observed. Since the target response rate was not achieved, accrual was stopped and CDDP as a single agent in ES was judged unworthy of further assessment.

Original languageEnglish
Article numbere26650
JournalPediatric Blood and Cancer
Volume64
Issue number12
DOIs
Publication statusPublished - Dec 1 2017

Keywords

  • cisplatin
  • Ewing sarcoma
  • metastatic

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group'. Together they form a unique fingerprint.

Cite this